GPR132 (G-Protein Coupled Receptor 132) Modulators for Neurodegeneration

GPR132 (G-Protein Coupled Receptor 132) Modulators for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR132 (G-Protein Coupled Receptor 132) Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Small molecule modulators</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Lipid-based approaches</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GPR132 (G2A, G-Protein Coupled Receptor 132)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Proton-sensing GPCR modulator</td>
</tr>
<tr>
<td class="label">Endogenous Activators</td>
<td>Protons (H⁺), lysophosphatidylcholine</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled, Gq-coupled</td>
</tr>
</table>

GPR132, also known as G2 accumulation (G2A), is a proton-sensing G-protein coupled receptor that is activated by extracellular acidosis and certain lipid metabolites. It is widely expressed in immune cells and neuronal tissue, where it mediates cellular responses to metabolic stress and inflammation. GPR132 modulators represent a novel therapeutic approach for neurodegenerative diseases through stress-sensing and immune modulation. [@lp2017]

GPR132 Biology

GPR132 is encoded by the [GPR132](/genes/gpr132) gene. Key features include:

GPR132 (G-Protein Coupled Receptor 132) Modulators for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR132 (G-Protein Coupled Receptor 132) Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Small molecule modulators</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Lipid-based approaches</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GPR132 (G2A, G-Protein Coupled Receptor 132)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Proton-sensing GPCR modulator</td>
</tr>
<tr>
<td class="label">Endogenous Activators</td>
<td>Protons (H⁺), lysophosphatidylcholine</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled, Gq-coupled</td>
</tr>
</table>

GPR132, also known as G2 accumulation (G2A), is a proton-sensing G-protein coupled receptor that is activated by extracellular acidosis and certain lipid metabolites. It is widely expressed in immune cells and neuronal tissue, where it mediates cellular responses to metabolic stress and inflammation. GPR132 modulators represent a novel therapeutic approach for neurodegenerative diseases through stress-sensing and immune modulation. [@lp2017]

GPR132 Biology

GPR132 is encoded by the [GPR132](/genes/gpr132) gene. Key features include:

• pH-Sensitive: Activated by extracellular acidosis (pH 6.0-7.0)
• Additional Ligands: Certain lipid metabolites (lysophosphatidylcholine)
• Signaling: Gi-coupled (primary), Gq-coupled in some contexts
• Expression: Macrophages, microglia, T cells, neurons, astrocytes
• Function: Cellular stress sensing, immune regulation

Mechanism of Action

GPR132 modulators work through stress-sensing and anti-inflammatory effects:

Key Mechanisms

Therapeutic Potential

Alzheimer's Disease

GPR132 modulators may benefit AD through:

• Reduction of neuroinflammation
• Protection against metabolic stress
• Support of neuronal survival
• Potential modulation of amyloid responses

Parkinson's Disease

GPR132 modulators are relevant for PD:

• Acidic environments in substantia nigra
• Protection of dopaminergic neurons
• Reduction of microglial activation
• Cellular stress adaptation

Other Applications

• Stroke
• Traumatic Brain Injury
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• Metabolic disorders with CNS involvement

Drug Development

GPR132 is an early-stage target:

Drug Properties

Research Status

GPR132 remains an emerging target:

• Limited selective compounds
• Complex ligand pharmacology
• Further understanding of CNS function needed
• Potential for combination with other proton-sensing GPCR targets

References

Related Pages

• [Proton-Sensing GPCRs](/therapeutics/gpr65-modulators-neurodegeneration)
• [Oxidative Stress Therapy](/therapeutics/antioxidant-therapy-neurodegeneration)
• [Stress Response](/therapeutics/cellular-stress-response-therapy-neurodegeneration)
• [GPR132 Gene](/genes/gpr132)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;